Probi Future Growth

Future criteria checks 2/6

Probi is forecast to grow earnings and revenue by 9.9% and 6.5% per annum respectively. EPS is expected to grow by 10.2% per annum. Return on equity is forecast to be 6.7% in 3 years.

Key information

9.9%

Earnings growth rate

10.2%

EPS growth rate

Biotechs earnings growth	37.0%
Revenue growth rate	6.5%
Future return on equity	6.7%
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:PROBS - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	772	100	157	177	1
12/31/2023	736	90	142	161	1
12/31/2022	683	81	140	158	1
6/30/2022	658	79	77	132	N/A
3/31/2022	642	75	104	155	N/A
12/31/2021	658	83	112	154	N/A
9/30/2021	673	79	129	169	N/A
6/30/2021	709	93	164	207	N/A
3/31/2021	731	105	105	149	N/A
12/31/2020	717	93	100	143	N/A
9/30/2020	699	97	57	97	N/A
6/30/2020	645	85	87	132	N/A
3/31/2020	646	88	132	170	N/A
12/31/2019	626	86	138	174	N/A
9/30/2019	623	84	136	164	N/A
6/30/2019	650	90	128	143	N/A
3/31/2019	623	81	140	154	N/A
12/31/2018	604	76	114	128	N/A
9/30/2018	561	53	103	120	N/A
6/30/2018	525	34	77	98	N/A
3/31/2018	544	29	75	100	N/A
12/31/2017	612	69	119	146	N/A
9/30/2017	687	98	140	166	N/A
6/30/2017	643	117	114	136	N/A
3/31/2017	544	118	110	127	N/A
12/31/2016	443	102	71	90	N/A
9/30/2016	286	74	34	52	N/A
6/30/2016	248	60	56	74	N/A
3/31/2016	234	54	N/A	52	N/A
12/31/2015	216	49	N/A	62	N/A
9/30/2015	220	52	N/A	74	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROBS's forecast earnings growth (9.9% per year) is above the savings rate (0.9%).

Earnings vs Market: PROBS's earnings (9.9% per year) are forecast to grow slower than the UK market (10.3% per year).

High Growth Earnings: PROBS's earnings are forecast to grow, but not significantly.

Revenue vs Market: PROBS's revenue (6.5% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: PROBS's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PROBS's Return on Equity is forecast to be low in 3 years time (6.7%).

Probi Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Recent updates

Probi AB (publ) Announces CFO Changes

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Probi AB (Publ) Launches Probi Sense

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Probi AB (publ) Announces Management Changes

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies